Helicobacter pylori Infections - Pipeline Review, H2 2016

Date: July 13, 2016
Pages: 75
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: HDE662E0927EN
Leaflet:

Download PDF Leaflet

Helicobacter pylori Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Helicobacter pylori Infections - Pipeline Review, H2 2016’, provides an overview of the Helicobacter pylori Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Helicobacter pylori Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Helicobacter pylori Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Helicobacter pylori Infections
  • The report reviews pipeline therapeutics for Helicobacter pylori Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Helicobacter pylori Infections therapeutics and enlists all their major and minor projects
  • The report assesses Helicobacter pylori Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Helicobacter pylori Infections
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Helicobacter pylori Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Helicobacter pylori Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Helicobacter pylori Infections Overview
Therapeutics Development
Pipeline Products for Helicobacter pylori Infections - Overview
Pipeline Products for Helicobacter pylori Infections - Comparative Analysis
Helicobacter pylori Infections - Therapeutics under Development by Companies
Helicobacter pylori Infections - Therapeutics under Investigation by Universities/Institutes
Helicobacter pylori Infections - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Helicobacter pylori Infections - Products under Development by Companies
Helicobacter pylori Infections - Products under Investigation by Universities/Institutes
Helicobacter pylori Infections - Companies Involved in Therapeutics Development
Daewoong Pharmaceutical Co., Ltd.
Debiopharm International SA
EpiVax, Inc.
Frost Biologic, Inc.
ImevaX GmbH
ImmunoBiology Limited
Recce Pty Ltd
RedHill Biopharma Ltd.
Sequella, Inc.
Sigmoid Pharma Limited
Helicobacter pylori Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(amoxicillin sodium + omeprazole sodium + rifabutin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Debio-1453 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWJ-1325 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FROST-900 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Helicobacter pylori [strain Hel-305] (multivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Helicobacter pylori vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Helicobacter pylori vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Helicobacter pylori vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Helicobacter pylori vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HPi-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMX-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RECCE-327 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Helicobacter Pylori Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit DNA Synthesis for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SQ-109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Helicobacter pylori Infections - Dormant Projects
Helicobacter pylori Infections - Product Development Milestones
Featured News & Press Releases
Apr 18, 2016: RedHill Announces Positive FDA Meeting on RHB-105 Path to Approval and Planned Confirmatory Phase III Study for H. pylori Infection
Mar 08, 2016: RedHill Biopharma Reports Successful Final Results of Phase III Study with RHB-105 for H. pylori Infection
Mar 01, 2016: RedHill Biopharma Provides Update on RHB-105
Sep 08, 2015: RedHill Announces Standard-of-Care Eradication Data from the RHB-105 Phase III Study Further Supporting the Study’s Positive Results
Aug 26, 2015: Recipharm Signs Agreement with RedHill Biopharma for Manufacturing of RHB-105 for treatment of H. pylori infection
Jun 15, 2015: RedHill Biopharma Successfully Meets Primary Endpoint in Phase III Study of RHB-105 for H. pylori Infection
Jun 15, 2015: RedHill Biopharma to Host Conference Call to Review Positive Phase III Top-Line Results with RHB-105 for H. pylori Infection
Jun 08, 2015: RedHill Biopharma Completes Treatment of Last Patient with RHB-105 in Phase III Study
Jun 03, 2015: RedHill Biopharma Provides Update on Development Pipeline and Expected Timing for RHB-105 Phase III Top-Line Results
May 18, 2015: RedHill Biopharma’s Investor Webcast Forum Provides Update on the RHB-105 Phase III Program and Potential H. Pylori Eradication Market
May 07, 2015: RedHill Biopharma to Host Investor Webcast Forum Following Completion of RHB-105 Dosing in Phase III Study
Apr 27, 2015: RedHill Biopharma Announces Completion of Patient Enrollment in a Phase III Study of RHB-105 for H. pylori Infection
Apr 16, 2015: RedHill Biopharma Receives Notice of Allowance for Additional U.S. Patent for RHB-105 H. pylori Bacterial Infection Treatment
Nov 10, 2014: FDA Grants QIDP Fast-Track Designation To RedHill Biopharma's Phase 3 H. Pylori Drug RHB-105
Aug 27, 2014: RedHill Biopharma Provides Update on Expansion of Ongoing RHB-105 Phase III Study, Targeting Broadened H. pylori Indication Authorized by FDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Helicobacter pylori Infections, H2 2016
Number of Products under Development for Helicobacter pylori Infections - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Helicobacter pylori Infections - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
Helicobacter pylori Infections - Pipeline by Debiopharm International SA , H2 2016
Helicobacter pylori Infections - Pipeline by EpiVax, Inc., H2 2016
Helicobacter pylori Infections - Pipeline by Frost Biologic, Inc., H2 2016
Helicobacter pylori Infections - Pipeline by ImevaX GmbH, H2 2016
Helicobacter pylori Infections - Pipeline by ImmunoBiology Limited, H2 2016
Helicobacter pylori Infections - Pipeline by Recce Pty Ltd, H2 2016
Helicobacter pylori Infections - Pipeline by RedHill Biopharma Ltd., H2 2016
Helicobacter pylori Infections - Pipeline by Sequella, Inc., H2 2016
Helicobacter pylori Infections - Pipeline by Sigmoid Pharma Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Helicobacter pylori Infections - Dormant Projects, H2 2016

LIST OF FIGURES

Number of Products under Development for Helicobacter pylori Infections, H2 2016
Number of Products under Development for Helicobacter pylori Infections - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

Helicobacter pylori Infections - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: